Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential multiple ascending doses of solnatide in moderate-to-severe ARDS
2017-003855-47Phase 2Completed
- Sponsor
- APEPTICO
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) and pulmonary edema comparing Solnatide with Placebo (2 arms). Primary endpoint: Safety. Started Jan 2018; status: completed.
02
Drugs
solnatide
03
Conditions
acute respiratory distress syndrome (ARDS)pulmonary edema
Beyond the preview
Go deeper on 2017-003855-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003855-47.